WT1 and neoplasm: Therefore, until compounds that directly inhibit the EWSR1-WT1 fusion are developed, the best short-term strategy to eradicating this aggressive pediatric sarcoma is indirect targeting of pathways that the EWSR1-WT1 fusion relies on to mediate tumor growth and survival.